Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.13 USD | -1.07% | -2.28% | -0.89% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Financials (USD)
Sales 2024 * | 663M | Sales 2025 * | 166M | Capitalization | 8.97B |
---|---|---|---|---|---|
Net income 2024 * | 4.25B | Net income 2025 * | -1.01B | EV / Sales 2024 * | 5.01 x |
Net cash position 2024 * | 5.65B | Net cash position 2025 * | 4.39B | EV / Sales 2025 * | 27.6 x |
P/E ratio 2024 * |
2.15
x | P/E ratio 2025 * |
-8.48
x | Employees | 904 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.81% |
Latest transcript on Roivant Sciences Ltd.
1 day | -1.07% | ||
1 week | -2.28% | ||
Current month | +2.11% | ||
1 month | -0.62% | ||
3 months | +2.96% | ||
6 months | +26.33% | ||
Current year | -0.89% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 16-02-29 |
Richard Pulik
DFI | Director of Finance/CFO | - | 21-09-27 |
Eric Venker
PSD | President | 37 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 23-03-12 | |
Keith Manchester
BRD | Director/Board Member | 55 | 13-12-31 |
Dan Gold
BRD | Director/Board Member | 56 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 11.13 | -1.07% | 2,569,934 |
24-05-09 | 11.25 | +0.36% | 3,958,851 |
24-05-08 | 11.21 | -1.49% | 5,092,520 |
24-05-07 | 11.38 | -1.90% | 3,753,769 |
24-05-06 | 11.6 | +1.84% | 3,445,432 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.89% | 8.97B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- ROIV Stock